Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 2/20 | 0.32 |
| ▸ | SLCO1B1 | Q9Y6L6 | 2/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19715730 | 0.88 | KDM4C (0.32) | ABCB11SLCO1B1KDM4CNPC1RAB9A | |
| SCHEMBL29411818 | 0.88 | NPC1 (0.34) | ABCB11SLCO1B1KDM4CNPC1RAB9A | |
| SCHEMBL19715528 | 0.88 | NPC1 (0.34) | ABCB11SLCO1B1KDM4CNPC1RAB9A | |
| SCHEMBL19715615 | 0.85 | SLCO1B1 (0.38) | ABCB11SLCO1B1KDM4CNPC1RAB9A | |
| SCHEMBL29411851 | 0.82 | SLCO1B1 (0.37) | ABCB11SLCO1B1KDM4CNPC1RAB9A | |
| SCHEMBL19715614 | 0.82 | SLCO1B1 (0.37) | ABCB11SLCO1B1KDM4CNPC1RAB9A | |
| SCHEMBL19715572 | 0.82 | SLCO1B1 (0.37) | ABCB11SLCO1B1KDM4CNPC1RAB9A | |
| SCHEMBL29411767 | 0.82 | SLCO1B1 (0.37) | ABCB11SLCO1B1KDM4CNPC1RAB9A | |
| SCHEMBL19715752 | 0.81 | ABCB11 (0.35) | ABCB11SLCO1B1KDM4CNPC1RAB9A | |
| SCHEMBL19728935 | 0.80 | ABCB11 (0.34) | ABCB11SLCO1B1KDM4CNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360759-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | SYNGENE INTERNATIONAL LIMITED (IN) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360759-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | ABCB11 2022/4885SLCO1B1 1507/4885KDM4C 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.